NEW YORK – Point-of-care diagnostic firm Nanomix announced on Monday that it has entered a Middle East distribution agreement with IPS Genomix for Nanomix's eLab system and tests.
IPS Genomix, a medical diagnostics distributor, will market and distribute the eLab system, the Nanomix S1 Panel Assay, and future eLab test products in multiple countries in the Middle East. Ahmed Yacout, the CEO of IPS, said in a statement that his firm has an "aggressive launch effort planned in four countries in the Middle East as early as this month."
Financial and other terms of the deal were not disclosed.
Nanomix Chief Commercial Officer John Hardesky said in a statement, "Adding IPS, and the Middle East, to our growing distribution portfolio will serve Nanomix to accelerate our commercial rollout of the eLab system."
In July, San Leandro, California-based Nanomix signed a deal with Biotron to distribute the eLab system and S1 panel in Israel.
The eLab system is a mobile immunoassay and chemistry diagnostic system for use at the point of care, and the S1 Panel Assay provides quantitative results for procalcitonin, C-reactive protein, and lactate from venous whole blood or plasma. The test is intended to help diagnose critical infections, including sepsis, and runs on the eLab Analyzer, returning results in 12 minutes. It received CE marking for use with whole blood in May.